2024 ICD-10-CM Diagnosis Code D09.9

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

• Adenocarcinoma in situ in villous adenoma
• Carcinoma in situ
• Common bile duct surgical margin, involved by tumor
• Intraepithelial squamous cell carcinoma
• Squamous cell carcinoma in situ
• Surgical bile duct margin involved by carcinoma in situ
• Surgical bile duct margin uninvolved by carcinoma in situ
• Surgical bronchial margin involved by squamous cell carcinoma in situ
• Surgical bronchial margin involved by tumor
• Surgical common bile duct margin involved by in situ carcinoma
• Surgical common bile duct margin uninvolved by in situ carcinoma
• Surgical cystic duct margin involved by in situ carcinoma
• Surgical cystic duct margin uninvolved by in situ carcinoma
• Surgical deep margin involved by in situ carcinoma
• Surgical deep margin uninvolved by in situ carcinoma
• Surgical distal margin involved by in situ carcinoma
• Surgical distal margin involved by in situ carcinoma/adenoma
• Surgical distal margin involved by tumor
• Surgical distal margin involved by tumor
• Surgical distal margin uninvolved by in situ carcinoma
• Surgical distal margin uninvolved by in situ carcinoma/adenoma
• Surgical distal mucosal margin involved by in situ carcinoma
• Surgical distal mucosal margin uninvolved by in situ carcinoma
• Surgical ductal margin uninvolved by in situ carcinoma
• Surgical lateral margin involved by in situ carcinoma
• Surgical lateral margin involved by in situ carcinoma/adenoma
• Surgical lateral margin uninvolved by in situ carcinoma
• Surgical lateral margin involved by in situ carcinoma
• Surgical lateral margin involved by tumor
• Surgical lateral margin involved by tumor
• Surgical lateral margin involved by tumor
• Surgical lateral margin uninvolved by in situ carcinoma
• Surgical margin involved by in situ carcinoma
• Surgical margin involved by in situ carcinoma/adenoma
• Surgical margin uninvolved by in situ carcinoma
• Surgical margin uninvolved by in situ carcinoma/adenoma
• Surgical mucosal margin involved by in situ carcinoma
• Surgical mucosal margin uninvolved by in situ carcinoma
• Surgical pancreatic duct margin involved by in situ carcinoma
• Surgical pancreatic duct margin uninvolved by in situ carcinoma
• Surgical pancreatic parenchymal margin involved by in situ carcinoma
• Surgical parenchymal margin finding
• Surgical proximal margin involved by in situ carcinoma
• Surgical proximal margin involved by in situ carcinoma/adenoma
• Surgical proximal margin uninvolved by in situ carcinoma
• Surgical proximal margin uninvolved by in situ carcinoma/adenoma
• Surgical proximal mucosal margin involved by in situ carcinoma
• Surgical proximal mucosal margin uninvolved by in situ carcinoma

Clinical Information

• Carcinoma in Situ

  a lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.

D09.9 is grouped with Diagnostic Related Groups - MS-DRG Mapping

Diagnostic Related Groups (DRGs) are a classification system used to group together diagnosis codes for the purpose of reimbursement and healthcare management. DRGs are used to standardize the way hospitals and other providers are paid for inpatient services. In this system patients are grouped together based on their principal diagnosis in areas referred to as Major Diagnostic Categories (MDC). Once a patient is assigned a particular diagnostic category, providers receive a predetermined payment rate for the services rendered. This reimbursement rate is often fixed and is meant to cover the cost of care for that patient. Reimbursement is also affected by the relative weight of a diagnostic related group based on the severity of a patient's illness and the associated cost of care during hospitalization.

Diagnostic related groups encourage healthcare providers to focus on quality and efficiency in patient care while managing costs effectively. The diagnosis code is present in the following groups for version MS-DRG V41.0 applicable from 10/01/2023 through 09/30/2024.

The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.

Convert D09.9 to ICD-9-CM

• ICD-9-CM Code: 234.9 - Ca in situ NOS

Table of Neoplasms

This code is referenced in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.

Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.

Patient Education

Cancer

Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.

Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Most treatment plans may include surgery, radiation and/or chemotherapy. Some may involve hormone therapy, immunotherapy or other types of biologic therapy, or stem cell transplantation.

NIH: National Cancer Institute

Code History

• FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
• FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
• FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
• FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
• FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
• FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
• FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
• FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
• FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.